Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment

Journal of Addiction Medicine

Volumn 6, Issue 3, 2012, Pages 233-239

  Zickmund, Susan L ^a,b   Campbell, Scott A ^c   Tirado, Carlos F ^d   Zook, Carolyn L ^a,e   Weinrieb, Robert M ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Center for Health Equity Research and Promotion   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Barriers to antiviral therapy; Hepatitis C; Opioid agonist treatment; Provider communication; Stigmatization

Indexed keywords

ANTIVIRUS AGENT; OPIATE AGONIST; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN;

ARTICLE; ATTITUDE TO HEALTH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; FATIGUE; FEAR; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; LOWEST INCOME GROUP; MALE; MEDICAL CARE; MEDICAL INFORMATION; NAUSEA; OPIATE SUBSTITUTION TREATMENT; PERCEPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RACE; RANDOMIZED CONTROLLED TRIAL; SEMI STRUCTURED INTERVIEW; THERAPY DELAY; TREATMENT INDICATION;

ADULT; ANTIVIRAL AGENTS; ATTITUDE TO HEALTH; COHORT STUDIES; COMORBIDITY; COMPREHENSION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERVIEW, PSYCHOLOGICAL; MALE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT REFUSAL;

EID: 84868563192     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31825f491b     Document Type: Article

References (39)

1. Anonymous. Management of hepatitis C: NIH consensus development conference. Hepatology 1997;26(suppl 1):IS-156S.
2. Anonymous. NIH consensus statement on management of hepatitis C: 2002. NIH consensus & state-of-the-science statements. Hepatology 2002;19(3):1-46.
3. Banwell C, Bammer G, Gifford SM, O'Brien ML. Australian lesbian and bisexual women's health and social experiences of living with hepatitis C. Health Care Women Int 2005;26(4):340-354.
4. Brener L, Treloar C. Alcohol and other drug treatment experiences of hepatitis C-positive and negative clients: implications for hepatitis C treatment. Aust Health Rev 2009;33(1):100-106.
5. Canfield KM, Smyth E, Batki SL. Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. Subst Use Misuse 2010;45(4): 496-514.
6. Crockett B, Gifford SM. "Eyes Wide Shut": narratives of women living with hepatitis C in Australia. Women Health 2004;39(4):117-137.
7. Crofts N, Louie R, Loff B. The next plague: stigmatization and discrimination related to hepatitis C virus infection in Australia. Health Hum Rights 1997;2(2):86-97.
8. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. Patients' experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns 2006;62(1):148-155.
9. Fried MW, ShiffmanML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-982.
10. Gifford SM, O'Brien ML, Bammer G, Banwell C, Stoove M. Australian women's experiences of living with hepatitis C virus: results from a crosssectional survey. J Gastroenterol Hepatol 2003;18(7):841-850.
11. Grebely J,Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008;93(1/2):141-147.
12. Grundy G, Beeching N. Understanding social stigma in women with hepatitis C. Nurs Stand 2004;19(4):35-39.
13. Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006;18(1):59-82.
14. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007;88(1):49-53.
15. Harris KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010;4(1):20-26.
16. Hopwood M, Treloar C. Receiving a hepatitis C-positive diagnosis. Intern Med J 2004;34(9/10):526-531.
17. Hu SW, Lai HR, Liao PH. Comparing dental students' knowledge of and attitudes toward hepatitis B virus-, hepatitis C virus-, and HIV-infected patients in Taiwan. AIDS Patient Care STDS 2004;18(10):587-593.
18. Kroeker KL, Bain VG, Shaw-Stiffel T, Fong TL, Yoshida EM. Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States. Liver Int 2008;28(9):1250-1255.
19. Kwiatkowski CF, Fortuin CK, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002;97(10):1289-1294.
20. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41-52.
21. Litwin AH, Harris KA Jr, Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009;37(1):32-40.
22. McCormick PA, Keavney M, O'Toole S, Moloney J. Methadone and HCV treatment. Ir Med J 2008;101(10):316-317.
23. Miller W, Crabtree BF. Primary care research: a multi typology and qualitative road map. In: Crabtree BF, Miller WL, eds. Doing Qualitative Research. London: Sage Press, 1992. pp 3-30.
24. Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008;103(6):905-918.
25. Robaeys G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 2005;68(1):55-67.
26. Schafer A, Scheurlen M, Felten M, Kraus MR. Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients. Eur J Gastroenterol Hepatol 2005;17(12):1387-1394.
27. Shehab TM, Orrego M, Chunduri R, Lok AS. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003;98(3):639-644.
28. Shehab TM, Sonnad S,Gebremariam A, Schoenfeld P. Knowledge of hepatitis C screening and management by internal medicine residents: trends over 2 years. Am J Gastroenterol 2002;97(5):1216-1222.
29. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007;19(9):741-747.
30. Treloar C, Holt M. Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev 2008;32(3):570-576.
31. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010;17:839-844.
32. Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. Qual Health Res 2009;19:1321-1334.
33. Walley AY, White MC, Kushel MB, Song YS, Tulsky JP. Knowledge of any interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005;28(2):181-187.
34. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90(10):1562-1569.
35. Wright NM, Tompkins CN, Jones L. Exploring risk perception and behaviour of homeless injecting drug users diagnosed with hepatitis C. Health Soc Care Community 2005;13(1):75-83.
36. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, Labrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004;39(4):999-1007.
37. Zickmund S, Ho EY,Masuda M, Ippolito L, Labrecque DR. "They treated me like a leper." Stigmatization and the quality of life of patients with hepatitis C.J Gen Intern Med 2003;18(10):835-844.
38. Zickmund SL, Brown KE, Bielefeldt K. A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease? Dig Dis Sci 2007;52(10):2550-2556.
39. Zickmund SL, Bryce CL, Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM. Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Eur J Gastroenterol Hepatol 2006;18(4):381-388.